Verona Pharma plc to Post Q4 2023 Earnings of ($0.32) Per Share, Wedbush Forecasts (NASDAQ:VRNA)

Verona Pharma plc (NASDAQ:VRNAGet Rating) – Research analysts at Wedbush issued their Q4 2023 EPS estimates for shares of Verona Pharma in a research note issued on Tuesday, May 3rd. Wedbush analyst L. Moussatos anticipates that the company will post earnings per share of ($0.32) for the quarter. Wedbush also issued estimates for Verona Pharma’s FY2025 earnings at $1.04 EPS.

VRNA has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Verona Pharma in a research report on Tuesday, January 25th. Zacks Investment Research upgraded shares of Verona Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Wednesday, April 6th.

VRNA opened at $4.05 on Thursday. The firm has a 50 day moving average price of $4.74 and a 200-day moving average price of $5.33. Verona Pharma has a twelve month low of $3.66 and a twelve month high of $7.87. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.09 and a quick ratio of 5.09.

Verona Pharma (NASDAQ:VRNAGet Rating) last posted its earnings results on Thursday, March 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.10.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its position in shares of Verona Pharma by 123.0% during the third quarter. Morgan Stanley now owns 8,194 shares of the company’s stock valued at $45,000 after buying an additional 4,520 shares during the last quarter. Geode Capital Management LLC bought a new stake in Verona Pharma in the 3rd quarter valued at $58,000. Lindbrook Capital LLC purchased a new stake in Verona Pharma in the 4th quarter worth $67,000. IPG Investment Advisors LLC bought a new position in shares of Verona Pharma during the 4th quarter valued at about $80,000. Finally, Millennium Management LLC purchased a new position in shares of Verona Pharma during the third quarter valued at about $81,000. 61.19% of the stock is owned by institutional investors and hedge funds.

In other news, insider Kathleen A. Rickard sold 112,800 shares of the business’s stock in a transaction dated Friday, April 8th. The stock was sold at an average price of $0.59, for a total value of $66,552.00. Following the transaction, the insider now directly owns 2,606,128 shares in the company, valued at $1,537,615.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kathleen A. Rickard sold 59,720 shares of the stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $0.54, for a total value of $32,248.80. Following the sale, the insider now owns 2,546,408 shares of the company’s stock, valued at approximately $1,375,060.32. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

About Verona Pharma (Get Rating)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Featured Stories

Earnings History and Estimates for Verona Pharma (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.